Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDxHealth SA

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY TO HOST CONFERENCE CALL WITH LIVE Q&A, AUGUST 13, 2026, AT 4:30PM ET / 22:30 CET IRVINE, CALIFORNIA  JULY 30, 2026 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AFTER MARKET CLOSE ON THURSDAY, AUGUST 13, 2026. TITLE: MDXHEALTH PRESENTS SECOND QUARTER 2026 FINANCIAL RESULTS ANDCORPORATE UPDATE CONFERENCE CALL AND WEBCAST DATE: AUGUST 13, 2026 TIME: 4:30PM ET/ 22:30 CET CONFERENCE CALL D IAL-IN DETAILS: UNITED STATES: 1-833-309-3473 BELGIUM: 0800 72 519 UNITED KINGDOM: 0808 101 1183 CONFERENCE ID:  MDX2Q26 WEBCAST: HTTPS://VIAVID.WEBCASTS.COM/STARTHERE.JSP?EI=1768432&TP_KEY=E5DEE9DBEF THE WEBCAST SHOULD BE ACCESSED 15 MINUTES PRIOR TO THE CONFERENCE CALL START TIME.

MDXHEALTH TO RELEASE SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 13

MDXHEALTH ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM MARKET VALUE OF LISTED SECURITIES DEFICIENCY IRVINE, CALIFORNIA  JULY 24, 2026 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (THE COMPANY OR MDXHEALTH), A LEADER IN UROLOGY-FOCUSED PRECISION DIAGNOSTICS, TODAY ANNOUNCED THAT THE COMPANY RECEIVED AN ADDITIONAL NOTIFICATION LETTER (THE ADDITIONAL LETTER) FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) RELATED TO THE RECENT REDUCTION IN THE PRICE FOR THE COMPANY'S ORDINARY SHARES. THE INITIAL NOTICE, REPORTED BY THE COMPANY IN ITS FORM 6-K FILED ON JULY 2, 2026, RELATED TO THE COMPANY'S NON-COMPLIANCE WITH THE $1.00 MINIMUM BID PRICE REQUIREMENT SET FORTH IN NASDAQ LISTING RULE 5550(A)(2) FOR CONTINUED LISTING.

MDXHEALTH ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM MARKET VALUE OF LISTED SECURITIES DEFICIENCY

IRVINE, CALIFORNIA JULY 2, 2026 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (THE "COMPANY" OR "MDXHEALTH"), A LEADER IN UROLOGY-FOCUSED PRECISION DIAGNOSTICS, TODAY ANNOUNCED THAT THE COMPANY RECEIVED A NOTIFICATION LETTER (THE NOTIFICATION LETTER) FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC (NASDAQ), DATED JUNE 30, 2026, NOTIFYING THE COMPANY THAT IT IS NOT IN COMPLIANCE WITH THE MINIMUM BID PRICE REQUIREMENT SET FORTH IN NASDAQ LISTING RULE 5550(A)(2) FOR CONTINUED LISTING ON THE NASDAQ CAPITAL MARKET. THIS PRESS RELEASE IS ISSUED PURSUANT TO NASDAQ LISTING RULE 5810(B), WHICH REQUIRES PROMPT DISCLOSURE UPON THE RECEIPT OF A DEFICIENCY NOTIFICATION.

MDXHEALTH ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY

MDXHEALTH ANNOUNCES PEER-REVIEWED PUBLICATION OF OXFORD GPS-PROMPT STUDY IN EUROPEAN UROLOGY ONCOLOGY, ESTABLISHING SCIENTIFIC FOUNDATION FOR THE LANDMARK GPS-PROTECT RANDOMIZED CONTROLLED TRIAL IRVINE, CALIFORNIA  JUNE 29, 2026 MDXHEALTH SA (NASDAQ: MDXH) (THE "COMPANY" OR "MDXHEALTH"), A LEADER IN UROLOGY-FOCUSED PRECISION DIAGNOSTICS, TODAY ANNOUNCED THE PEER-REVIEWED PUBLICATION OF THE OXFORD GPS-PROMPT STUDY IN EUROPEAN UROLOGY ONCOLOGY, ONE OF THE WORLD'S LEADING JOURNALS IN GENITOURINARY ONCOLOGY. THE PUBLICATION REPRESENTS THE FIRST MAJOR PEER-REVIEWED MILESTONE FROM THE OXFORD COLLABORATION AND SERVES AS THE FOUNDATION FOR EVIDENCE TO BE PRODUCED BY THE LANDMARK GPS-PROTECT STUDY.

MDXHEALTH ANNOUNCES PEER-REVIEWED PUBLICATION OF OXFORD GPS-PROMPT STUDY IN EUROPEAN UROLOGY ONCOLOGY, ESTABLISHING SCIENTIFIC FOUNDATION FOR THE LANDMARK GPS-PROTECT RANDOMIZED CONTROLLED TRIAL

MDXHEALTH REPORTS Q1-2026 RESULTS CONFERENCE CALL WITH Q&A TODAY AT 4:30 PM ET / 22:30 CET IRVINE, CALIFORNIA  MAY 13, 2026 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (THE "COMPANY" OR "MDXHEALTH"), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. MICHAEL K.

MDXHEALTH REPORTS Q1-2026 RESULTS

MDXHEALTH SA (NASDAQ: MDXH), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MAR

MDXHEALTH TO RELEASE FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 13

MDXHEALTH HIGHLIGHTS DATA FROM OXFORD'S PROMPT STUDY DEMONSTRATING THE GENOMIC PROSTATE SCORE GPS TEST PREDICTS ADVERSE OUTCOMES ACROSS MULTIPLE TREATMENT SETTINGS AT EAU 2026

MDXHEALTH TO PRESENT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE UPDATE ON FEBRUARY 26 COMPANY TO HOST CONFERENCE CALL WITH LIVE Q&A, FEBRUARY 26, 2026, AT 4:30PM ET / 22:30 CET IRVINE, CALIFORNIA  FEBRUARY 12, 2026 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AFTER MARKET CLOSE ON THURSDAY, FEBRUARY 26, 2026. TITLE: MDXHEALTH PRESENTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ANDCORPORATE UPDATE CONFERENCE CALL AND WEBCAST DATE: FEBRUARY 26, 2026 TIME: 4:30PM ET/ 22:30 CET CONFERENCE CALL D IAL-IN DETAILS: UNITED STATES: 1-844-825-9789 INT'L: 1-412-317-5180 BELGIUM: 0800 38 961 UNITED KINGDOM: 0800 279 9489 CONFERENCE ID:  10206764 WEBCAST: HTTPS://VIAVID.WEBCASTS.COM/STARTHERE.JSP?EI=1753070&TP_KEY=27BCE7D4DE THE WEBCAST SHOULD BE ACCESSED 15 MINUTES PRIOR TO THE CONFERENCE CALL START TIME.

MDXHEALTH TO PRESENT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE UPDATE ON FEBRUARY 26

MDXHEALTH REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 REVENUES, ISSUES 2026 REVENUE GUIDANCE, AND AMENDS EARNOUT TERMS WITH EXACT SCIENCES

MDXHEALTH REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 REVENUES,ISSUES 2026 REVENUE GUIDANCE, AND AMENDS EARNOUT TERMS WITH EXACT SCIENCES

MDXHEALTH AND UNIVERSITY OF OXFORD TO VALIDATE GPS TEST IN LARGEST RANDOMIZED TRIAL OF TREATMENT EFFECTIVENESS IN PATIENTS WITH LOCALIZED PROSTATE CANCER

MDxHealth SA

MDXH

Price

Financial Reports

No items found.

Press Releases

MDxHealth SA

MDXH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MDXH